Turning Point Therapeutics (Turning Point Therapeutics) EPS (Diluted) : $-6.90 (TTM As of Jun. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Turning Point Therapeutics EPS (Diluted)?

Turning Point Therapeutics's Earnings per Share (Diluted) for the three months ended in Jun. 2022 was $-2.48. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $-6.90.

Turning Point Therapeutics's EPS (Basic) for the three months ended in Jun. 2022 was $-2.48. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2022 was $-6.90.

Turning Point Therapeutics's EPS without NRI for the three months ended in Jun. 2022 was $-2.48. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2022 was $-6.90.

During the past 3 years, the average EPS without NRIGrowth Rate was -42.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 5 years, Turning Point Therapeutics's highest 3-Year average EPS without NRI Growth Rate was -42.50% per year. The lowest was -51.30% per year. And the median was -46.90% per year.

Turning Point Therapeutics EPS (Diluted) Historical Data

The historical data trend for Turning Point Therapeutics's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Turning Point Therapeutics EPS (Diluted) Chart

Turning Point Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

EPS (Diluted)

-1.11

-1.66

-2.99

-3.85

-4.80

Turning Point Therapeutics Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
EPS (Diluted)	Get a 7-Day Free Trial														-1.14	-1.34	-1.58	-1.50	-2.48

Competitive Comparison of Turning Point Therapeutics's EPS (Diluted)

For the Biotechnology subindustry, Turning Point Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Turning Point Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Turning Point Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Turning Point Therapeutics's PE Ratio falls into.

Turning Point Therapeutics EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Turning Point Therapeutics's Diluted EPS for the fiscal year that ended in Dec. 2021 is calculated as

Diluted EPS (A: Dec. 2021 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-236.551	-	0)	/	49.265
	=	-4.80

Turning Point Therapeutics's Diluted EPS for the quarter that ended in Jun. 2022 is calculated as

Diluted EPS (Q: Jun. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-123.088	-	0)	/	49.703
	=	-2.48

EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.90

Turning Point Therapeutics (NAS:TPTX) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Turning Point Therapeutics EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Turning Point Therapeutics's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Turning Point Therapeutics (Turning Point Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Turning Point Therapeutics Inc (NAS:TPTX) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

10628 Science Center Drive, Suite 200, San Diego, CA, USA, 92121

Website

https://www.tptherapeutics.com

Turning Point Therapeutics Inc is a clinical-stage biopharmaceutical company involved in designing and developing molecule, targeted oncology therapies to address limitations of existing therapies. It owns a pipeline of next-generation tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in both TKI-naive and TKI-pretreated patients. The company's lead drug candidate, repotrectinib, is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors.

Executives

Paolo Tombesi	officer: EVP & Chief Financial Officer	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Steve M Sabus	officer: SVP & Chief Commercial Officer	10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Brian Sun	officer: SVP & General Counsel	C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121
Mohammad Hirmand	officer: EVP and Chief Medical Officer	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Athena Countouriotis	director, officer: President & CEO	C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Siegfried Reich	officer: EVP & Chief Scientific Officer	10505 ROSELLE STREET SAN DIEGO CA 92121
Andrew John Partridge	officer: EVP & Chief Commercial Officer	C/O CENTREXION THERAPEUTICS CORPORATION 200 STATE STREET BOSTON MA 02109
Annette North	officer: EVP, General Counsel & Secty.	C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
Mark J Alles	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Van Hoose Kyri K.	officer: Principal Accounting Officer	C/O TURNING POINT THERAPEUTICS, INC., 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Barbara W. Bodem	director	C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Brian Lee Baker	officer: VP of Finance and Admin.	C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DR., STE. 225 SAN DIEGO CA 92121
Yi Larson	officer: EVP & Chief Financial Officer	C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Jingrong Jean Cui	director, 10 percent owner, officer: Chief Scientific Officer	C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DR., STE. 225 SAN DIEGO CA 92121
Simeon George	director	161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428